Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 5/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19835753 | 0.78 | HTR2A (0.48) | HTR2AHTR2CHTR2B | |
| SCHEMBL22280802 | 0.75 | TRPA1 (0.37) | HSD11B1MAPK1 | |
| SCHEMBL4086101 | 0.69 | SMN1; SMN2 (0.39) | HSD11B1SMN1; SMN2MAPK1KCNJ1KCNH2 | |
| SCHEMBL4085555 | 0.69 | — | — | |
| SCHEMBL10733139 | 0.67 | AR (0.50) | HTR2AHTR2CHTR2BSMN1; SMN2AR | |
| SCHEMBL31621318 | 0.67 | AR (0.50) | HTR2AHTR2CHTR2BSMN1; SMN2AR | |
| SCHEMBL19835774 | 0.67 | ADRA2A (0.47) | HSD11B1 | |
| SCHEMBL29758963 | 0.67 | KCNJ1 (0.43) | HTR2AHTR2CHTR2BARKCNJ1 | |
| SCHEMBL30711985 | 0.67 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPK1 | |
| SCHEMBL17008842 | 0.67 | KCNJ1 (0.43) | HTR2AHTR2CHTR2BARKCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| CN-101495460-A | HSP90 inhibitor | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247524-A1 | HSP90 Inhibitor | HSP90AB1, HSP90B1, HSP90AA1 | HTR2A 3407/4885HTR2C 3348/4885HTR2B 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.